1. Home
  2. FEIM vs MYGN Comparison

FEIM vs MYGN Comparison

Compare FEIM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frequency Electronics Inc.

FEIM

Frequency Electronics Inc.

HOLD

Current Price

$52.97

Market Cap

494.3M

Sector

Industrials

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.88

Market Cap

551.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEIM
MYGN
Founded
1961
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
494.3M
551.8M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
FEIM
MYGN
Price
$52.97
$5.88
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$42.50
$11.00
AVG Volume (30 Days)
237.9K
877.4K
Earning Date
03-12-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
163.76
N/A
EPS
2.17
N/A
Revenue
$69,852,000.00
$825,300,000.00
Revenue This Year
$5.52
$0.03
Revenue Next Year
$17.07
$5.38
P/E Ratio
$24.38
N/A
Revenue Growth
16.06
0.21
52 Week Low
$13.69
$3.76
52 Week High
$61.47
$15.47

Technical Indicators

Market Signals
Indicator
FEIM
MYGN
Relative Strength Index (RSI) 52.40 38.06
Support Level $51.39 $5.47
Resistance Level $59.80 $6.15
Average True Range (ATR) 3.53 0.36
MACD -1.32 -0.02
Stochastic Oscillator 21.73 24.33

Price Performance

Historical Comparison
FEIM
MYGN

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: